, Volume 225, Issue 1, pp 227–239 | Cite as

The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions

  • André Schmidt
  • Michael Kometer
  • Rosilla Bachmann
  • Erich Seifritz
  • Franz Vollenweider
Original Investigation



Both glutamate and serotonin (5-HT) play a key role in the pathophysiology of emotional biases. Recent studies indicate that the glutamate N-methyl-d-aspartate (NMDA) receptor antagonist ketamine and the 5-HT receptor agonist psilocybin are implicated in emotion processing. However, as yet, no study has systematically compared their contribution to emotional biases.


This study used event-related potentials (ERPs) and signal detection theory to compare the effects of the NMDA (via S-ketamine) and 5-HT (via psilocybin) receptor system on non-conscious or conscious emotional face processing biases.


S-ketamine or psilocybin was administrated to two groups of healthy subjects in a double-blind within-subject placebo-controlled design. We behaviorally assessed objective thresholds for non-conscious discrimination in all drug conditions. Electrophysiological responses to fearful, happy, and neutral faces were subsequently recorded with the face-specific P100 and N170 ERP.


Both S-ketamine and psilocybin impaired the encoding of fearful faces as expressed by a reduced N170 over parieto-occipital brain regions. In contrast, while S-ketamine also impaired the encoding of happy facial expressions, psilocybin had no effect on the N170 in response to happy faces.


This study demonstrates that the NMDA and 5-HT receptor systems differentially contribute to the structural encoding of emotional face expressions as expressed by the N170. These findings suggest that the assessment of early visual evoked responses might allow detecting pharmacologically induced changes in emotional processing biases and thus provides a framework to study the pathophysiology of dysfunctional emotional biases.


Glutamate Serotonin Ketamine Psilocybin Emotional processing biases Event-related potential Visual awareness Non-conscious Conscious 


  1. Abel KM, Allin MP, Kucharska-Pietura K, David A, Andrew C, Williams S, Brammer MJ, Phillips ML (2003) Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study. Neuroreport 14:387–391PubMedCrossRefGoogle Scholar
  2. Adolphs R (2003) Cognitive neuroscience of human social behaviour. Nat Rev Neurosci 4:165–178PubMedCrossRefGoogle Scholar
  3. Amaral DG, Behniea H, Kelly JL (2003) Topographic organization of projections from the amygdala to the visual cortex in the macaque monkey. Neuroscience 118:1099–1120PubMedCrossRefGoogle Scholar
  4. Ashley V, Vuilleumier P, Swick D (2004) Time course and specificity of event-related potentials to emotional expressions. Neuroreport 15:211–216PubMedCrossRefGoogle Scholar
  5. Balconi M, Lucchiari C (2008) Consciousness and arousal effects on emotional face processing as revealed by brain oscillations. A gamma band analysis. Int J Psychophysiol 67:41–46PubMedCrossRefGoogle Scholar
  6. Bar M, Tootell RB, Schacter DL, Greve DN, Fischl B, Mendola JD, Rosen BR, Dale AM (2001) Cortical mechanisms specific to explicit visual object recognition. Neuron 29:529–535PubMedCrossRefGoogle Scholar
  7. Batty M, Taylor MJ (2003) Early processing of the six basic facial emotional expressions. Brain Res Cogn Brain Res 17:613–620PubMedCrossRefGoogle Scholar
  8. Bernat E, Bunce S, Shevrin H (2001) Event-related brain potentials differentiate positive and negative mood adjectives during both supraliminal and subliminal visual processing. Int J Psychophysiol 42:11–34PubMedCrossRefGoogle Scholar
  9. Bhagwagar Z, Cowen PJ, Goodwin GM, Harmer CJ (2004) Normalization of enhanced fear recognition by acute SSRI treatment in subjects with a previous history of depression. Am J Psychiatry 161:166–168PubMedCrossRefGoogle Scholar
  10. Blau VC, Maurer U, Tottenham N, McCandliss BD (2007) The face-specific N170 component is modulated by emotional facial expression. Behav Brain Funct 3:7PubMedCrossRefGoogle Scholar
  11. Bressler SL, Tang W, Sylvester CM, Shulman GL, Corbetta M (2008) Top-down control of human visual cortex by frontal and parietal cortex in anticipatory visual spatial attention. J Neurosci 28:10056–10061PubMedCrossRefGoogle Scholar
  12. Brosch T, Sander D, Pourtois G, Scherer KR (2008) Beyond fear: rapid spatial orienting toward positive emotional stimuli. Psychol Sci 19:362–370PubMedCrossRefGoogle Scholar
  13. Browning M, Reid C, Cowen PJ, Goodwin GM, Harmer CJ (2007) A single dose of citalopram increases fear recognition in healthy subjects. J Psychopharmacol 21:684–690PubMedCrossRefGoogle Scholar
  14. Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX (2005) Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci 17:1497–1508PubMedCrossRefGoogle Scholar
  15. Deffke I, Sander T, Heidenreich J, Sommer W, Curio G, Trahms L, Lueschow A (2007) MEG/EEG sources of the 170-ms response to faces are co-localized in the fusiform gyrus. NeuroImage 35:1495–1501PubMedCrossRefGoogle Scholar
  16. Degabriele R, Lagopoulos J, Malhi G (2011) Neural correlates of emotional face processing in bipolar disorder: an event-related potential study. J Affect Disord 133:212–220PubMedCrossRefGoogle Scholar
  17. Del-Ben CM, Deakin JF, McKie S, Delvai NA, Williams SR, Elliott R, Dolan M, Anderson IM (2005) The effect of citalopram pretreatment on neuronal responses to neuropsychological tasks in normal volunteers: an FMRI study. Neuropsychopharmacology 30:1724–1734PubMedCrossRefGoogle Scholar
  18. Derogatis L (1994) SCL-90-R: Symptom Checklist-90-R. Administration, scoring and procedures manual. National Computer Systems, MinneapolisGoogle Scholar
  19. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:793–802Google Scholar
  20. Dima D, Stephan KE, Roiser JP, Friston KJ, Frangou S (2011) Effective connectivity during processing of facial affect: evidence for multiple parallel pathways. J Neurosci 31:14378–14385PubMedCrossRefGoogle Scholar
  21. Dittrich A (1975) Zusammenstellung eines Fragebogens (APZ) zur Erfassung abnormer psychischer Zustände [Construction of a questionnaire (APZ) for assessing abnormal mental states]. Z Klin Psychol Psychiatr Psychother 23:12–20Google Scholar
  22. Dittrich A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31:80–84PubMedCrossRefGoogle Scholar
  23. Eimer M, Holmes A (2002) An ERP study on the time course of emotional face processing. Neuroreport 13:427–431PubMedCrossRefGoogle Scholar
  24. Ekman P, Friesen W (1976) Pictures of facial affect. Consulting Psychologists, Palo AltoGoogle Scholar
  25. Elliott R, Zahn R, Deakin JF, Anderson IM (2011) Affective cognition and its disruption in mood disorders. Neuropsychopharmacology 36:153–182PubMedCrossRefGoogle Scholar
  26. Fairhall SL, Ishai A (2007) Effective connectivity within the distributed cortical network for face perception. Cereb Cortex 17:2400–2406PubMedCrossRefGoogle Scholar
  27. Feng N, Vollenweider FX, Minder EI, Rentsch K, Grampp T, Vonderschmitt DJ (1995) Development of a gas chromatography–mass spectrometry method for determination of ketamine in plasma and its application to human samples. Ther Drug Monit 17:95–100PubMedCrossRefGoogle Scholar
  28. Fichtenholtz HM, Hopfinger JB, Graham R, Detwiler JM, LaBar KS (2009) Event-related potentials reveal temporal staging of dynamic facial expression and gaze shift effects on attentional orienting. Soc Neurosci 4:317–331PubMedCrossRefGoogle Scholar
  29. Freese JL, Amaral DG (2005) The organization of projections from the amygdala to visual cortical areas TE and V1 in the macaque monkey. J Comp Neurol 486:295–317PubMedCrossRefGoogle Scholar
  30. Frühholz S, Jellinghaus A, Herrmann M (2011) Time course of implicit processing and explicit processing of emotional faces and emotional words. Biol Psychol 87:265–274PubMedCrossRefGoogle Scholar
  31. Gazzaley A, Cooney JW, McEvoy K, Knight RT, D’Esposito M (2005) Top-down enhancement and suppression of the magnitude and speed of neural activity. J Cogn Neurosci 17:507–517PubMedCrossRefGoogle Scholar
  32. Gouzoulis-Mayfrank E, Thelen B, Maier S, Heekeren K, Kovar KA, Sass H, Spitzer M (2002) Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans. Neuropsychobiology 45:205–212PubMedCrossRefGoogle Scholar
  33. Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, Greer GR (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68:71–78Google Scholar
  34. Harmer CJ (2008) Serotonin and emotional processing: does it help explain antidepressant drug action? Neuropharmacology 55:1023–1028PubMedCrossRefGoogle Scholar
  35. Harmer CJ, Bhagwagar Z, Perrett DI, Völlm BA, Cowen PJ, Goodwin GM (2003) Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology 28:148–152PubMedCrossRefGoogle Scholar
  36. Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM (2004) Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition. Am J Psychiatry 161:1256–1263PubMedCrossRefGoogle Scholar
  37. Hasler F, Bourquin D, Brenneisen R, Vollenweider FX (2002) Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man. J Pharm Biomed Anal 30:331–339PubMedCrossRefGoogle Scholar
  38. Hasler F, Grimberg U, Benz M, Huber T, Vollenweider F (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose–effect study. Psychopharmacology (Berl) 172:145–156CrossRefGoogle Scholar
  39. Herrington JD, Taylor JM, Grupe DW, Curby KM, Schultz RT (2011) Bidirectional communication between amygdala and fusiform gyrus during facial recognition. NeuroImage 56:2348–2355PubMedCrossRefGoogle Scholar
  40. Ishai A (2007) Sex, beauty and the orbitofrontal cortex. Int J Psychophysiol 63:181–185PubMedCrossRefGoogle Scholar
  41. Itier RJ, Taylor MJ (2004) N170 or N1? Spatiotemporal differences between object and face processing using ERPs. Cereb Cortex 14:132–142PubMedCrossRefGoogle Scholar
  42. Jaworska N, Thompson A, Shah D, Fisher D, Ilivitsky V, Knott V (2010) Electrocortical effects of acute tryptophan depletion on emotive facial processing in depression-prone individuals. Eur Neuropsychopharmacol 20:473–486PubMedCrossRefGoogle Scholar
  43. Kemp AH, Gray MA, Line P, Silberstein RB, Nathan PJ (2003) Preliminary electrophysiological evidence for modulation of the processing of negative effect by serotonin. Brain Cogn 51:198–200Google Scholar
  44. Kemp AH, Gray MA, Silberstein RB, Armstrong SM, Nathan PJ (2004) Augmentation of serotonin enhances pleasant and suppresses unpleasant cortical electrophysiological responses to visual emotional stimuli in humans. NeuroImage 22:1084–1096PubMedCrossRefGoogle Scholar
  45. Kerestes R, Labuschagne I, Croft RJ, O’Neill BV, Bhagwagar Z, Phan KL, Nathan PJ (2009) Evidence for modulation of facial emotional processing bias during emotional expression decoding by serotonergic and noradrenergic antidepressants: an event-related potential (ERP) study. Psychopharmacology (Berl) 202:621–634CrossRefGoogle Scholar
  46. Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX (2012) Psilocybin Biases Facial Recognition, Goal-Directed Behavior, and Mood State Toward Positive Relative to Negative Emotions Through Different Serotonergic Subreceptors. Biol Psychiatry. doi:10.1016/j.biopsych.2012.04.005
  47. Krolak-Salmon P, Fischer C, Vighetto A, Mauguière F (2001) Processing of facial emotional expression: spatio-temporal data as assessed by scalp event-related potentials. Eur J Neurosci 13:987–994PubMedCrossRefGoogle Scholar
  48. Krombholz A, Schaefer F, Boucsein W (2007) Modification of N170 by different emotional expression of schematic faces. Biol Psychol 76:156–162PubMedCrossRefGoogle Scholar
  49. Krystal J, Karper L, Seibyl J, Freeman G, Delaney R, Bremner J, Heninger G, Bowers MJ, Charney D (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199–214PubMedCrossRefGoogle Scholar
  50. Labuschagne I, Croft RJ, Phan KL, Nathan PJ (2010) Augmenting serotonin neurotransmission with citalopram modulates emotional expression decoding but not structural encoding of moderate intensity sad facial emotional stimuli: an event-related potential (ERP) investigation. J Psychopharmacol 24:1153–1164PubMedCrossRefGoogle Scholar
  51. Lee TW, Girolami M, Sejnowski TJ (1999) Independent component analysis using an extended infomax algorithm for mixed subgaussian and supergaussian sources. Neural Comput 11:417–441PubMedCrossRefGoogle Scholar
  52. Macmillan N, Creelman C (1991) Detection theory: a user’s guide. Cambridge University Press, CambridgeGoogle Scholar
  53. Marini F, Marzi T, Viggiano MP (2011) “Wanted!” The effects of reward on face recognition: electrophysiological correlates. Cogn Affect Behav Neurosci 11:627–643Google Scholar
  54. Morgan CJ, Mofeez A, Brandner B, Bromley L, Curran HV (2004) Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 29:208–218PubMedCrossRefGoogle Scholar
  55. Nathan PJ, Kemp AH, Harrison BJ (2003) Antidepressants and emotional processing. Neuropsychopharmacology 28:1383, author reply 1384–5PubMedCrossRefGoogle Scholar
  56. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, Craft S, Olney JW (1999) Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20:106–118PubMedCrossRefGoogle Scholar
  57. Nichols DE (2004) Hallucinogens. Pharmacol Ther 101:131–181PubMedCrossRefGoogle Scholar
  58. Noll LK, Mayes LC, Rutherford HJ (2012) Investigating the impact of parental status and depression symptoms on the early perceptual coding of infant faces: an event-related potential study. Soc Neurosci. doi:10.1080/17470919.2012.672457
  59. Nutt DJ, Forshall S, Bell C, Rich A, Sandford J, Nash J, Argyropoulos S (1999) Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur Neuropsychopharmacol 9(Suppl 3):S81–S86PubMedCrossRefGoogle Scholar
  60. Passie T, Seifert J, Schneider U, Emrich HM (2002) The pharmacology of psilocybin. Addict Biol 7:357–364PubMedCrossRefGoogle Scholar
  61. Pegna AJ, Landis T, Khateb A (2008) Electrophysiological evidence for early non-conscious processing of fearful facial expressions. Int J Psychophysiol 70:127–136PubMedCrossRefGoogle Scholar
  62. Pegna AJ, Darque A, Berrut C, Khateb A (2011) Early ERP modulation for task-irrelevant subliminal faces. Front Psychol 2:88PubMedCrossRefGoogle Scholar
  63. Pessoa L, Padmala S (2005) Quantitative prediction of perceptual decisions during near-threshold fear detection. Proc Natl Acad Sci U S A 102:5612–5617PubMedCrossRefGoogle Scholar
  64. Pessoa L, Japee S, Sturman D, Ungerleider LG (2006) Target visibility and visual awareness modulate amygdala responses to fearful faces. Cereb Cortex 16:366–375PubMedCrossRefGoogle Scholar
  65. Pourtois G, Vuilleumier P (2006) Dynamics of emotional effects on spatial attention in the human visual cortex. Prog Brain Res 156:67–91PubMedCrossRefGoogle Scholar
  66. Pourtois G, Grandjean D, Sander D, Vuilleumier P (2004) Electrophysiological correlates of rapid spatial orienting towards fearful faces. Cereb Cortex 14:619–633PubMedCrossRefGoogle Scholar
  67. Quednow BB, Kometer M, Geyer MA, Vollenweider FX (2011) Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology 37:630–640Google Scholar
  68. Rose M, Schmid C, Winzen A, Sommer T, Büchel C (2005) The functional and temporal characteristics of top-down modulation in visual selection. Cereb Cortex 15:1290–1298PubMedCrossRefGoogle Scholar
  69. Rossion B, Jacques C (2008) Does physical interstimulus variance account for early electrophysiological face sensitive responses in the human brain? Ten lessons on the N170. NeuroImage 39:1959–1979PubMedCrossRefGoogle Scholar
  70. Rossion B, Joyce CA, Cottrell GW, Tarr MJ (2003) Early lateralization and orientation tuning for face, word, and object processing in the visual cortex. NeuroImage 20:1609–1624PubMedCrossRefGoogle Scholar
  71. Sadeh B, Podlipsky I, Zhdanov A, Yovel G (2010) Event-related potential and functional MRI measures of face-selectivity are highly correlated: a simultaneous ERP-fMRI investigation. Hum Brain Mapp 31:1490–1501PubMedCrossRefGoogle Scholar
  72. Santesso DL, Meuret AE, Hofmann SG, Mueller EM, Ratner KG, Roesch EB, Pizzagalli DA (2008) Electrophysiological correlates of spatial orienting towards angry faces: a source localization study. Neuropsychologia 46:1338–1348PubMedCrossRefGoogle Scholar
  73. Schmidt A, Bachmann R, Kometer M, Csomor PA, Stephan KE, Seifritz E, Vollenweider FX (2011) Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments. Neuropsychopharmacology 37:865–875Google Scholar
  74. Schneider W, Eschman A, Zuccolotto A (2002) E-prime reference guide. Psychology Software Tools, PittsburghGoogle Scholar
  75. Schultz RT, Grelotti DJ, Klin A, Kleinman J, Van der Gaag C, Marois R, Skudlarski P (2003) The role of the fusiform face area in social cognition: implications for the pathobiology of autism. Philos Trans R Soc Lond B Biol Sci 358:415–427PubMedCrossRefGoogle Scholar
  76. Schyns PG, Petro LS, Smith ML (2007) Dynamics of visual information integration in the brain for categorizing facial expressions. Curr Biol 17:1580–1585PubMedCrossRefGoogle Scholar
  77. Sheehan D, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar G (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59:22–33PubMedGoogle Scholar
  78. Singer T, Kiebel SJ, Winston JS, Dolan RJ, Frith CD (2004) Brain responses to the acquired moral status of faces. Neuron 41:653–662PubMedCrossRefGoogle Scholar
  79. Smith ML (2011) Rapid processing of emotional expressions without conscious awareness. Cereb Cortex 22:1748–1760Google Scholar
  80. Sokhadze EM, Tasman A, Tamas R, El-Mallakh RS (2011) Event-related potential study of the effects of emotional facial expressions on task performance in euthymic bipolar patients. Appl Psychophysiol Biofeedback 36:1–13PubMedCrossRefGoogle Scholar
  81. Sprengelmeyer R, Jentzsch I (2006) Event related potentials and the perception of intensity in facial expressions. Neuropsychologia 44:2899–2906PubMedCrossRefGoogle Scholar
  82. Stekelenburg JJ, de Gelder B (2004) The neural correlates of perceiving human bodies: an ERP study on the body-inversion effect. Neuroreport 15:777–780PubMedCrossRefGoogle Scholar
  83. Studerus E, Gamma A, Vollenweider F (2010) Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One 5:e12412PubMedCrossRefGoogle Scholar
  84. Studerus E, Kometer M, Hasler F, Vollenweider FX (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 25:1434–1452PubMedCrossRefGoogle Scholar
  85. Tamietto M, de Gelder B (2010) Neural bases of the non-conscious perception of emotional signals. Nat Rev Neurosci 11:697–709PubMedCrossRefGoogle Scholar
  86. Vollenweider F, Kometer M (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11:642–651PubMedCrossRefGoogle Scholar
  87. Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J (1997) Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 7:9–24PubMedCrossRefGoogle Scholar
  88. Vuilleumier P, Pourtois G (2007) Distributed and interactive brain mechanisms during emotion face perception: evidence from functional neuroimaging. Neuropsychologia 45:174–194PubMedCrossRefGoogle Scholar
  89. Williams LM, Liddell BJ, Rathjen J, Brown KJ, Gray J, Phillips M, Young A, Gordon E (2004) Mapping the time course of nonconscious and conscious perception of fear: an integration of central and peripheral measures. Hum Brain Mapp 21:64–74PubMedCrossRefGoogle Scholar
  90. Wittchen HU, Pfister H (1997) DIA-X-Interviews: Manual für Screening-Verfahren und Interview. Swets & Zeitlinger, FrankfurtGoogle Scholar
  91. Wronka E, Walentowska W (2011) Attention modulates emotional expression processing. Psychophysiology 48:1047–1056Google Scholar
  92. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864Google Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • André Schmidt
    • 1
  • Michael Kometer
    • 1
  • Rosilla Bachmann
    • 1
  • Erich Seifritz
    • 2
  • Franz Vollenweider
    • 1
  1. 1.Neuropsychopharmacology and Brain Imaging, University Hospital of PsychiatryUniversity of ZurichZurichSwitzerland
  2. 2.Clinic of Affective Disorders and General Psychiatry, University Hospital of PsychiatryUniversity of ZurichZurichSwitzerland

Personalised recommendations